Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
6 results
  • Liver Cancer, Gastric (Stomach) Cancer, Cervical Cancer

20-577          Phase I

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on

  • Head and Neck Cancer, Ovarian Cancer, Breast Cancer, Cervical Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer (View details on

  • Lung Cancer, Kidney Cancer, Head and Neck Cancer, Sarcoma, Cervical Cancer

19-090          Phase I

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms (View details on

  • Lung Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Pancreatic Cancer, Breast Cancer

22-015          Phase I

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a SA and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (View details on

  • Uterine Cancer, Cervical Cancer, Breast Cancer, Gallbladder and Bile Duct Cancers, Bladder Cancer, Lung Cancer

21-043          Phase II

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (View details on

  • Melanoma, Endometrial Cancer, Chordoma, Cervical Cancer, Breast Cancer, Bladder Cancer, Esophageal Cancer, Lung Cancer, Pancreatic Cancer, Ovarian Cancer

20-650          Phase II

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on

Showing 1 - 10 of 6 results